Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $17.89 USD
Change Today +0.16 / 0.90%
Volume 2.4M
OPK On Other Exchanges
New York
Tel Aviv
As of 8:04 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

opko health inc (OPK) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/21/15 - $18.29
52 Week Low
10/13/14 - $8.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for OPKO HEALTH INC (OPK)

opko health inc (OPK) Related Businessweek News

View More BusinessWeek News

opko health inc (OPK) Details

OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics. The company develops various solutions to diagnose, treat, and prevent various conditions, including point-of-care tests, molecular diagnostics tests, laboratory developed tests, and proprietary pharmaceuticals and vaccines. Its products include 4Kscore test that measures the blood plasma levels of four different prostate-derived kallikrein proteins. The company’s lead product candidates comprise Rayaldee to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; and Alpharen to treat hyperphosphatemia in stage 5 patients on chronic hemodialysis. It is also developing CTP, hGH-CTP for the treatment of growth hormone deficiency; Factor VII-CTP for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX; Inspiromatic, a powder inhaler for use in the therapy for asthma, chronic obstructive pulmonary disease, cystic fibrosis, and other respiratory diseases; and rolapitant for the prevention of chemotherapy induced nausea and vomiting, as well as focuses on the development of a long-acting oxyntomdulinGLP-1/glucagon dual receptor agonist. In addition, the company is developing Claros1 immunoassay instrument system that provides rapid blood test results and enables complex tests to be run in point-of-care settings; drugs for the treatment cancer, heart disease, metabolic disorders, and various genetic anomalies; and has various therapeutic agents in clinical development for the treatment of respiratory disorders. Further, it operates a full-service medical laboratory specializing in urologic pathology. OPKO Health, Inc. is based in Miami, Florida.

674 Employees
Last Reported Date: 02/27/15

opko health inc (OPK) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $500.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $300.0K
Vice Chairman and Chief Technical Officer
Total Annual Compensation: $490.0K
Executive Vice President of Administration an...
Total Annual Compensation: $480.0K
Compensation as of Fiscal Year 2014.

opko health inc (OPK) Key Developments

OPKO Health, Inc. Announces Publication of Study Using Kallikrein Biomarkers of the 4Kscore® Test in Large Community-Based Referral Cohort

OPKO Health, Inc. announced the online publication of a study entitled A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort in the journal European Urology. The study shows that the four kallikrein panel of biomarkers utilized in the OPKO 4Kscore® Test (Total PSA, Free PSA, Intact PSA and hK2) accurately identifies risk for aggressive prostate cancer prior to prostate biopsy in a population of men referred for prostate biopsy based on Total PSA level and a free PSA to Total PSA ratio. The study evaluated the accuracy of the four kallikrein biomarkers in the 4Kscore along with age, DRE and an algorithm (4K algorithm) to predict risk of aggressive prostate cancer in a large community-based setting at Skåne University Hospital, Malmö, Sweden. Like the 4Kscore US Validation study, the Malmö study was conducted on men being referred for prostate biopsy, but in this study, the criteria for referral explicitly included high-risk men with an elevated PSA (greater than or equal to 3 ng/mL) and a low percentage of Free PSA to Total PSA (less than or equal to 20%). These inclusion criteria selected for men with a higher risk for having aggressive prostate cancer than the cohort studied in the 4Kscore US Validation Study. Of the 749 men recruited for the trial, a total of 156 men (21%) were found to have aggressive prostate cancer defined as Gleason score greater than or equal to 7. The results demonstrated that the 4K algorithm discriminated men with aggressive prostate cancer from men who did not have aggressive disease with an area under the curve (AUC) of 0.78. The study also reported that even in this high risk patient population, a substantial number of biopsies (25%) could have been avoided. A decision curve analysis also demonstrated a significant net benefit for the use of the 4K algorithm in this cohort compared to performing biopsy on all men, the current standard of care.

Opko Health, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Opko Health, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenues of $30.1 million compared to $22.3 million a year ago. Operating loss was $56.9 million compared to $30.3 million a year ago. Loss before income taxes and investment losses was $110.8 million compared to $42.4 million a year ago. Net loss was $118.1 million compared to $45.1 million a year ago. Net loss attributable to common shareholders was $117.1 million compared to $44.6 million a year ago. Basic and diluted loss per share was $0.26 compared to $0.11 a year ago.

Opko Health, Inc. to Report Q1, 2015 Results on May 11, 2015

Opko Health, Inc. announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on May 11, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OPK:US $17.89 USD +0.16

OPK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OPK.
View Industry Companies

Industry Analysis


Industry Average

Valuation OPK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 80.0x
Price/Book 9.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 77.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OPKO HEALTH INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at